AstraZeneca's MedImmune Acquisition Should Receive Regulatory Approval - Seeking Alpha

AstraZeneca's MedImmune Acquisition Should Receive Regulatory Approval - Seeking Alpha: "The M & A Researcher submits: The AstraZeneca (AZN) -MedImmune Inc. (MEDI) acquisition deal is the largest biotech deal to surface since the Immunex/Amgen (AMGN) transaction almost five years ago. There is one simple factor that applies to biotech deals with respect to competition-related reviews (particularly the DOJ/FTC): a specific niche overlap(s) must exist where one or both of the companies are dominant in that niche in order to draw any sort of antitrust interest."